In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
The in vitro activities of buforin II, cecropin P1, and magainin II, alone and in combination with six clinically used antimicrobial agents, against 12 clinical isolates of Stenotrophomonas maltophilia were investigated. Antimicrobial activities were measured by MIC and time-kill studies. The isolates were susceptible to the peptides at concentrations in the range of 0.50 to 16 microg/ml. Synergy was observed when the peptides were combined with polymyxin E, meropenem, ceftazidime, piperacillin, and clarithromycin.
Giacometti
A
A
Institute of Infectious Diseases and Public Health, University of Ancona, Ancona, Italy. cmalinf@popcsi.unian.it
Cirioni
O
O
Del Prete
M S
MS
Barchiesi
F
F
Fortuna
M
M
Drenaggi
D
D
Scalise
G
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D002442:Ceftazidime / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004357:Drug Synergism; D054806:Magainins; D000077731:Meropenem; D010455:Peptides / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology; D029867:Xenopus Proteins
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D054806:Magainins; D010455:Peptides; D011506:Proteins; D013845:Thienamycins; D029867:Xenopus Proteins; C097849:buforin II; C053301:magainin 2 peptide, Xenopus; D002442:Ceftazidime; D000077731:Meropenem; C070016:cecropin P1-LI; D010878:Piperacillin; D003091:Colistin